Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Rituximab in DMARD Resistant RA
NCT01593332Phase 4Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Jul 2010
- Primary completion
- Sep 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised trial of rituximab in rheumatoid arthritis (RA) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Disease Activity Score 28 at 24 weeks and European League Against Rheumatism Response Criteria at 24 weeks. Started Jul 2010; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01593332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01593332.